Skip to contentI
IGC Pharma, Inc.
I
IGCIGC Pharma, Inc. Q2 2026 · 10-Q
Revenue$265.00K$265.00K−19.2% vs Q2 2025 Net Income-$2.94M-$2.94MN/M vs Q2 2025 EPS Diluted-$0.03-$0.03N/M vs Q2 2025 Gross Profit$48,000−68.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IGC Pharma, Inc. · CIK 1326205 · Engraved from SEC EDGAR
Operating Cash Flowderived-$1,350,000N/M Free Cash Flowderived-$1,355,000N/M Margins · derivedGross margin18.1%−28.8 pt vs Q2 2025
Operating margin-1050.6%−469.8 pt vs Q2 2025
Net margin-1107.9%−620.4 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end